Tag : AD

AI/ML

Model predicts cognitive decline due to Alzheimer’s, up to two years out

Newsemia
A new model developed at MIT can help predict if patients at risk for Alzheimer’s disease will experience clinically significant cognitive decline due to the...
Pediatrics

Ancient Caribbean children helped with grocery shopping in AD 400

Newsemia
Researchers have long thought that snail and clam shells found at Caribbean archaeological sites were evidence of ‘starvation food’ eaten in times when other resources...
Latest News

Riassunto: Concessa ad Axonics® l’ampliamento della marcatura CE sulle etichette del primo e unico sistema di neuromodulazione sacrale approvato per l’uso con la risonanza magnetica dell’intero corpo

Newsemia
IRVINE, California–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), un’azienda operante nel settore delle tecnologie mediche specializzata nello sviluppo e nella commercializzazione di innovativi dispositivi impiantabili...
Latest News

Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) – Other Company Programs in AD Continue

Newsemia
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the decision to discontinue CREAD 1 and...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy